Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP-2 study of trastuzumab and pertuzumab added to neoadjuvant chemoradiation for HER2-positive resectable esophageal adenocarcinoma
NL-OMON59832Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and pertuzumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: overall survival. Started Mar 2022; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59832.